Wedbush Reiterates Outperform on Foghorn Therapeutics, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Foghorn Therapeutics (NASDAQ:FHTX) and maintained a $13 price target.
August 09, 2024 | 2:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Foghorn Therapeutics and maintained a $13 price target.
The reiteration of an Outperform rating and the maintenance of a $13 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100